210 related articles for article (PubMed ID: 35416291)
1. Natural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients.
Hagemann K; Riecken K; Jung JM; Hildebrandt H; Menzel S; Bunders MJ; Fehse B; Koch-Nolte F; Heinrich F; Peine S; Schulze Zur Wiesch J; Brehm TT; Addo MM; Lütgehetmann M; Altfeld M
Eur J Immunol; 2022 Aug; 52(8):1297-1307. PubMed ID: 35416291
[TBL] [Abstract][Full Text] [Related]
2. Impact of SARS-CoV-2 vaccination on FcγRIIIA/CD16 dynamics in Natural Killer cells: relevance for antibody-dependent functions.
Capuano C; De Federicis D; Ciuti D; Turriziani O; Angeloni A; Anastasi E; Giannini G; Belardinilli F; Molfetta R; Alvaro D; Palmieri G; Galandrini R
Front Immunol; 2023; 14():1285203. PubMed ID: 38045702
[TBL] [Abstract][Full Text] [Related]
3. Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2.
Saini P; Adeniji OS; Bordoloi D; Kinslow J; Martinson J; Parent DM; Hong KY; Koshy J; Kulkarni AJ; Zilberstein NF; Balk RA; Moy JN; Giron LB; Tracy RP; Keshavarzian A; Muthumani K; Landay A; Weiner DB; Abdel-Mohsen M
mBio; 2023 Feb; 14(1):e0339322. PubMed ID: 36728420
[TBL] [Abstract][Full Text] [Related]
4. Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2.
Grant MD; Bentley K; Fielding CA; Hatfield KM; Ings DP; Harnum D; Wang EC; Stanton RJ; Holder KA
JCI Insight; 2023 Aug; 8(15):. PubMed ID: 37338994
[TBL] [Abstract][Full Text] [Related]
5. The development and kinetics of functional antibody-dependent cell-mediated cytotoxicity (ADCC) to SARS-CoV-2 spike protein.
Chen X; Rostad CA; Anderson LJ; Sun HY; Lapp SA; Stephens K; Hussaini L; Gibson T; Rouphael N; Anderson EJ
Virology; 2021 Jul; 559():1-9. PubMed ID: 33774551
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Against SARS-CoV-2 After Natural Infection Is More Potent Than After Vaccination.
Rieke GJ; van Bremen K; Bischoff J; ToVinh M; Monin MB; Schlabe S; Raabe J; Kaiser KM; Finnemann C; Odainic A; Kudaliyanage A; Latz E; Strassburg CP; Boesecke C; Schmidt SV; Krämer B; Rockstroh JK; Nattermann J
J Infect Dis; 2022 May; 225(10):1688-1693. PubMed ID: 35323975
[TBL] [Abstract][Full Text] [Related]
7. NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.
Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Pérez Potti A; Rivera Ballesteros O; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Söderdahl G; Österborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Loré K; Sobkowiak MJ; Gabarrini G; Healy K; Sällberg Chen M; Alici E; Björkström NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren HG
Mol Med; 2022 Feb; 28(1):20. PubMed ID: 35135470
[TBL] [Abstract][Full Text] [Related]
8. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
9. Durable natural killer cell response after three doses of SARS-CoV-2 inactivated vaccine in HIV-infected individuals.
Yang X; Wang X; Zhang X; Ding H; Wang H; Huang T; Zhang G; Duan J; Xia W; Su B; Jin C; Wu H; Zhang T
Chin Med J (Engl); 2023 Dec; 136(24):2948-2959. PubMed ID: 38018259
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies.
Fielding CA; Sabberwal P; Williamson JC; Greenwood EJD; Crozier TWM; Zelek W; Seow J; Graham C; Huettner I; Edgeworth JD; Price DA; Morgan PB; Ladell K; Eberl M; Humphreys IR; Merrick B; Doores K; Wilson SJ; Lehner PJ; Wang ECY; Stanton RJ
Elife; 2022 May; 11():. PubMed ID: 35587364
[TBL] [Abstract][Full Text] [Related]
11. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
12. High-affinity FcγRIIIa genetic variants and potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe COVID-19.
Vietzen H; Danklmaier V; Zoufaly A; Puchhammer-Stöckl E
Genet Med; 2022 Jul; 24(7):1449-1458. PubMed ID: 35488894
[TBL] [Abstract][Full Text] [Related]
13. Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma.
Tso FY; Lidenge SJ; Poppe LK; Peña PB; Privatt SR; Bennett SJ; Ngowi JR; Mwaiselage J; Belshan M; Siedlik JA; Raine MA; Ochoa JB; Garcia-Diaz J; Nossaman B; Buckner L; Roberts WM; Dean MJ; Ochoa AC; West JT; Wood C
PLoS One; 2021; 16(3):e0247640. PubMed ID: 33661923
[TBL] [Abstract][Full Text] [Related]
14. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
[TBL] [Abstract][Full Text] [Related]
15. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.
Di Vito C; Calcaterra F; Coianiz N; Terzoli S; Voza A; Mikulak J; Della Bella S; Mavilio D
Front Immunol; 2022; 13():888248. PubMed ID: 35844604
[TBL] [Abstract][Full Text] [Related]
16. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
Front Immunol; 2022; 13():876533. PubMed ID: 35711413
[TBL] [Abstract][Full Text] [Related]
17. Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein.
Hong Y; Guo H; Wei M; Zhang Y; Fang M; Cheng T; Li Z; Ge S; Yao X; Yuan Q; Xia N
J Virol Methods; 2022 Sep; 307():114564. PubMed ID: 35671888
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
[TBL] [Abstract][Full Text] [Related]
19. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
[TBL] [Abstract][Full Text] [Related]
20. Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic.
Brehm TT; Thompson M; Ullrich F; Schwinge D; Addo MM; Spier A; Knobloch JK; Aepfelbacher M; Lohse AW; Lütgehetmann M; Schulze Zur Wiesch J
Int J Hyg Environ Health; 2021 Sep; 238():113851. PubMed ID: 34601375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
